MK-2461 is a potent and selective inhibitor of the MET receptor tyrosine kinase, which plays a key role in tumor growth, metastasis, and angiogenesis. It is primarily investigated for its anticancer properties, especially in cancers where MET signaling is dysregulated, such as certain lung, gastric, liver, and kidney cancers. By blocking MET activation, MK-2461 suppresses downstream signaling pathways that drive cell proliferation and survival, making it a candidate for targeted cancer therapy. It has been used in preclinical studies to evaluate tumor response and resistance mechanisms, supporting the development of MET-targeted treatments. Its high selectivity also makes it a useful tool in pharmacological research to dissect MET-dependent biological processes.